ENCell’s investigational drug EN001 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Charcot-Marie-Tooth disease (CMT). CMT, a hereditary neuromuscular disorder, causes progressive muscle weakness and deformities in the hands and feet. In severe cases, it can lead to vision and hearing impairment. There are currently no approved treatments for the disorder. EN001 is a mesenchymal stem cell therapy developed using ENCell’s pr...